Testing effectiveness (Phase 2)Ended earlyNCT02269670
What this trial is testing
Phase II Study of Everolimus Beyond Progression
Who this might be right for
Estrogen Receptor-positive Breast CancerHER2-negative Breast CancerProgesterone Receptor-positive Breast Cancer+5 more
Emory University 3